{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:58:34Z","timestamp":1790521114423,"version":"4.1.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,13]]},"DOI":"10.1182\/blood.2020008119","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T02:12:38Z","timestamp":1611627158000},"page":"2704-2707","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma"],"prefix":"10.1182","volume":"137","author":[{"given":"Christopher R.","family":"Bolen","sequence":"first","affiliation":[{"name":"Bioinformatics & Computational Biology, Genentech Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mattiello","sequence":"additional","affiliation":[{"name":"Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Herold","sequence":"additional","affiliation":[{"name":"HELIOS-Klinikum Erfurt, Erfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huet","sequence":"additional","affiliation":[{"name":"Equipe Labellis\u00e9e Ligue Contre le Cancer, Cancer Research Centre of Lyon, Oullins, France;"},{"name":"Laboratoire d'H\u00e9matologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre B\u00e9nite, France;"},{"name":"Facult\u00e9 de Pharmacie de Lyon, Universit\u00e9 Claude Bernard Lyon-1, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Marcus","sequence":"additional","affiliation":[{"name":"HCA Healthcare, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Mir","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Equipe Labellis\u00e9e Ligue Contre le Cancer, Cancer Research Centre of Lyon, Oullins, France;"},{"name":"Service d\u2019H\u00e9matologie Clinique, Hospices Civils de Lyon et Universit\u00e9 Claude Bernard Lyon-1, Pierre-Benite, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, University Hospital of the Ludwig-Maximilians-University, Munich, Germany;"},{"name":"German Cancer Consortium, Heidelberg, Germany;"},{"name":"German Cancer Research Centre, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Z.","family":"Oestergaard","sequence":"additional","affiliation":[{"name":"Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Venstrom","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Foundation Medicine, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2021051315250391000_B1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2021051315250391000_B2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2021051315250391000_B3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2021051315250391000_B4","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021051315250391000_B5","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/blood-2018-99-114620","article-title":"A novel prognostic model that is superior to FLIPI-1 and FLIPI-2 and integrates clinical and treatment factors to predict progression-free survival and early treatment failure in patients with follicular lymphoma in the GALLIUM trial [abstract]","volume":"132","author":"Mir","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2021051315250391000_B6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2021051315250391000_B7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"2021051315250391000_B8","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"22","key":"2021051315250391000_B9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/bloodadvances.2016000786","article-title":"Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets","volume":"1","author":"Bolen","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2021051315250391000_B10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2021051315250391000_B11","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2019-129024","article-title":"1524 Validation of the PRIMA-prognostic index for patients treated with rituximab plus chemotherapy and refinement of prognostic parameters for patients on rituximab plus lenalidomide in the phase III RELEVANCE trial [abstract]","volume":"134","author":"Julia","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021051315250391000_B12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy [abstract]","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2021051315250391000_B13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"2021051315250391000_B14","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2021051315250391000_B15","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2021051315250391000_B16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.2019000560","article-title":"Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles","volume":"135","author":"Staiger","year":"2020","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/19\/2704\/1807061\/bloodbld2020008119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/19\/2704\/1807061\/bloodbld2020008119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T15:26:09Z","timestamp":1620919569000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/19\/2704\/475041\/Treatment-dependence-of-prognostic-gene-expression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":16,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008119","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]}}}